Literature DB >> 19706773

Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution.

Ian Campbell1, Kornelia Polyak, Izhak Haviv.   

Abstract

It is well established that carcinoma-associated fibroblasts (CAFs) differ phenotypically from fibroblasts associated with normal tissue, but the mechanisms underlying these differences remain controversial. Because CAFs can be propagated in vitro for extended periods and still maintain their cancer promoting phenotype, it has been proposed that they might have acquired somatic genetic alterations analogous to those observed in malignant epithelium. Whereas some investigators have reported frequent and profound genomic alterations in CAFs, other groups have found no such evidence. One striking common trait of those studies reporting frequent clonal somatic alterations in CAFs is the use of tissues and techniques which are well known to be highly prone to generating artefacts, such as limiting and poor quality DNA followed by highly multiplexed PCR-based analysis. We conclude that reported frequent clonal somatic mutations in CAFs are likely to be artefacts and are not the biological basis of the cancer promoting attributes of CAFs. [corrected]

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706773     DOI: 10.1158/0008-5472.CAN-08-4253

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

2.  Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct.

Authors:  Amy A Mrazek; Joseph R Carmical; Thomas G Wood; Mark R Hellmich; Mahmoud Eltorky; Frederick J Bohanon; Celia Chao
Journal:  Curr Cancer Ther Rev       Date:  2014-01

Review 3.  Stromal cells in tumor microenvironment and breast cancer.

Authors:  Yan Mao; Evan T Keller; David H Garfield; Kunwei Shen; Jianhua Wang
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

4.  Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI.

Authors:  Nima Nabavizadeh; Catherine Klifa; David Newitt; Ying Lu; Yunn-Yi Chen; Howard Hsu; Clark Fisher; Taku Tokayasu; Adam B Olshen; Paul Spellman; Joe W Gray; Nola Hylton; Catherine C Park
Journal:  Integr Biol (Camb)       Date:  2011-03-18       Impact factor: 2.192

Review 5.  Stromal biomarkers in breast cancer development and progression.

Authors:  Jenny A Rudnick; Charlotte Kuperwasser
Journal:  Clin Exp Metastasis       Date:  2012-06-10       Impact factor: 5.150

6.  Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α.

Authors:  Xiao-Ping Chai; Guang-Long Sun; Yan-Fen Fang; Li-Hong Hu; Xuan Liu; Xiong-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

7.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Authors:  Tomer Cooks; Ioannis S Pateras; Ohad Tarcic; Hilla Solomon; Aaron J Schetter; Sylvia Wilder; Guillermina Lozano; Eli Pikarsky; Tim Forshew; Nitzan Rosenfeld; Nitzan Rozenfeld; Noam Harpaz; Steven Itzkowitz; Curtis C Harris; Varda Rotter; Vassilis G Gorgoulis; Moshe Oren
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

Review 8.  Stromal androgen receptor in prostate development and cancer.

Authors:  Mandeep Singh; Ruchi Jha; Jonathan Melamed; Ellen Shapiro; Simon W Hayward; Peng Lee
Journal:  Am J Pathol       Date:  2014-08-01       Impact factor: 4.307

9.  Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

Authors:  Andriy Marusyk; Doris P Tabassum; Michalina Janiszewska; Andrew E Place; Anne Trinh; Andrii I Rozhok; Saumyadipta Pyne; Jennifer L Guerriero; Shaokun Shu; Muhammad Ekram; Alexander Ishkin; Daniel P Cahill; Yuri Nikolsky; Timothy A Chan; Mothaffar F Rimawi; Susan Hilsenbeck; Rachel Schiff; Kent C Osborne; Antony Letai; Kornelia Polyak
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

10.  Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Authors:  W Nathaniel Brennen; D Marc Rosen; Hao Wang; John T Isaacs; Samuel R Denmeade
Journal:  J Natl Cancer Inst       Date:  2012-08-21       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.